Published: 11.07.2026 at 12:09 PM,
Redaktion boerse-global.de
Current research shows a direct correlation between structural changes and an increased risk of neurodegenerative diseases.
Loss of Gray Matter
A significant British study involving 125,000 participants has yielded revealing results. Researchers conducted MRI scans on 11,000 women, revealing a substantial loss of gray matter.
Key areas affected include those responsible for memory and emotions—the hippocampus, the entorhinal cortex, and the anterior cingulate cortex. The reduction in estrogen levels measurably affects neurological integrity, and researchers have observed a correlation with Alzheimer’s disease risk.
Ongoing Research Initiatives
The Charité Berlin has launched the “Mapping Perimenopause” study. Over three years, the team will monitor 300 participants, aiming to understand how hormonal fluctuations influence mood, memory, and brain structure. The project is funded by the European Research Council.
Additionally, the LMU Munich is employing a new PET scanner that detects amyloid deposits early—crucial for dementia screening. A June 2026 study published in Nature Metabolism also indicates that long-term use of proton pump inhibitors may increase dementia risk by 44%.
Hormone Replacement Therapy: Effective, Yet Limited
Hormone replacement therapy (HRT/MHT) alleviates symptoms such as hot flashes, sleep disturbances, and “brain fog.” However, it doesn’t fully prevent structural damage to the brain. Experts from the European Menopause and Andropause Society caution that gray matter loss may continue despite hormone treatment.
Risk-benefit analysis remains pivotal: while therapy can increase breast cancer and thrombosis risks, it may lower mortality rates for certain patients, particularly those who have undergone oophorectomy. Experts recommend lifestyle changes focusing on diet, exercise, and stress management as complementary strategies.
Increased Diabetes Risk by 30%
New studies indicate that hormone replacement therapy does not provide complete protection against structural brain damage. What truly helps will be detailed in the latest report, offering early detection methods and practical steps for brain health. Secure your report now
Hormonal changes profoundly affect metabolic health. An early onset of menopause increases diabetes risk by 30%. The link between hormonal status and insulin resistance is evident in Polycystic Ovary Syndrome (PCOS). In spring 2026, 56 organizations renamed it as Polyendocrine Metabolic Ovarian Syndrome (PMOS), emphasizing the systemic metabolic component.
85% of PMOS patients show insulin resistance, with a fourfold increase in their Type 2 diabetes risk. New therapeutic options are emerging: In May 2026, the EMA recommended the approval of an oral semaglutide tablet for weight reduction. UK Biobank data from July 2026 reveal that diabetes risk is influenced 55% by lifestyle and 45% by genetics.
Disclaimer on our articles: No investment advice, no buying or selling recommendations. Information on prices, companies, and markets is without guarantee; subject to change at any time. Stock market transactions can lead to significant losses. Our contributions are fully or partially automated with AI support.
